|
[1]European Association for The Study of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[2]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int,2015,35(Suppl 1):78-81.
|
|
[3]KAO JH.HBeA g-positive chronic hepatitis B:why do I treat my patients with pegylated interferon?[J].Liver Int,2014,34(1):112-119.
|
|
[4]BUTI M.HBeA g-positive chronic hepatitis B:why do i treat my patients with nucleos(t)ide analogs?[J].Liver Int,2014,34(1):108-111.
|
|
[5]BAM RA,YANT SR,CIHLAR T.Tenofovir alafenamide is not a substrate for renal organic anion transporters(OATs)and does not exhibit OAT-dependent cytotoxicity[J].Antivir Ther,2014,19(7):687-692.
|
|
[6] AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty eight day safety and efficacy of tenofovir alafenamide(TAF)fumarate in chronic hepatitis B(CHB)patients[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.
|
|
[7]AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty-eight day safety,antiviral activity,and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J].J Hepatol,2015,62(3):533-540.
|
|
[8]YUEN MF,KIM J,KIM CR,et al.A randomized placebo-controlled,dose-finding study of oral LB80380 in HBeA g-positive patients with chronic hepatitis B[J].Antivir Ther,2006,11(8):977-983.
|
|
[9]LAI CL,AHN SH,LEE KS,et al.Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B[J].Gut,2014,63(6):996-1004.
|
|
[10]YUEN MF,AHN SH,LEE KS,et al.Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs.entecavir:results from a multicentre study[J].J Hepatol,2015,62(3):526-532.
|
|
[11]JIANG M,BROERING R,TRIPPLER M,et al.Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J].J Viral Hepat,2014,21(12):860-872.
|
|
[12]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.
|
|
[13]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,54(6):426-432.
|
|
[14]XU DZ,WANG XY,SHEN XL,et al.Results of a phaseⅢclinical trial with an HBsA g-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients:experiences and findings[J].J Hepatol,2013,59(3):450-456.
|
|
[15]VOLZ T,ALLWEISS L,BEN MM,et al.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J].J Hepatol,2013,58(5):861-867.
|
|
[16]HAEFELI WE,BLANK,MIKUS G,et al.Successful first administration of Myrcludex B,a first-in-class Hepatitis B and D Virus entry inhibitor,in humans[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.
|
|
[17]BOGOMOLOV P,VORONKOVA N,ALLWEISS L,et al.A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.
|
|
[18]BREZILLON N,BRUNELLE MN,MASSINET H,et al.Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Albu PA/SCID mice[J].PLoS One,2011,6(12):e25096.
|
|
[19]WU G,LIU B,ZHANG Y,et al.Preclinical characterization of GLS4,an inhibitor of hepatitis B virus core particle assembly[J].Antimicrob Agents Chemother,2013,57(11):5344-5354.
|
|
[20]WANG XY,WEI ZM,WU GY,et al.In vitro inhibition of HBV replication by a novel compound,GLS4,and its efficacy against adefovirdipivoxil-resistant HBV mutations[J].Antivir Ther,2012,17(5):793-803.
|
|
[21]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B[C]//61st annual meeting of the American Association for the Study of Liver Diseases.Boston,MA,2010.
|
|
[22]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that elicits durable immunological control of chronic HBV infection[C]//62nd annual meeting of the American Association for the Study of Liver Diseases(AASLD).San Francisco,CA,2011.
|
|
[23]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a second generation HBsA g release inhibitor with improved tolerability[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.
|
|
[24]WOODDELL CI,ROZEMA DB,HOSSBACH M,et al.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection[J].Mol Ther,2013,21(5):973-985.
|
|
[25]YUEN MF,CHAN H,GIVEN B,et al.PhaseⅡ,dose ranging study of ARC-520,a siRNA-based therapeutic,in patients with chronic hepatitis B virus infection[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.
|
|
[26]SEIGAL BA,CONNORS WH,FRALEY A,et al.The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library,and their optimization to give lead compounds with in vivo antitumor activity[J].J Med Chem,2015,58(6):2855-2861.
|
|
[27]EBERT G,ALLISON C,PRESTON S,et al.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J].Proc Natl Acad Sci U S A,2015,112(18):5803-5808.
|
|
[28]GAGGAR A,COESHOTT C,APELIAN D,et al.Safety,tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study[J].Vaccine,2014,32(39):4925-4931.
|
|
[29]REN XW,XU WR,ZOU MX,et al.A Compound elvucitabine pharmaceutical composition and its preparation method and uses:CN102652748A[P].2012-09-05.(in Chinese)任晓文,徐为人,邹美香,等.稳定的艾夫他滨药物组合物及其制备方法:CN102652748A[P].2012-09-05.
|
|
[30] LIM SG,LEE KS,CHUANG WL,et al.Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection:48 week analysis of a phase 2 study[J].J Clin Virol,2006,36(2):231-238.
|
|
[31]REDDY KR,MATELICH MC,UGARKAR BG,et al.Pradefovir:a prodrug that targets adefovir to the liver for the treatment of hepatitis B[J].J Med Chem,2008,51(3):666-676.
|
|
[32]IYER RK,MARQUIS J,HARTER M,et al.Preclinical studies of SB9200 for hepatitis treatment[C]//34th annual meeting of the American College of Toxicology.San Antonio,TX,2014.
|
|
[33]CUNNINGHAM ME,WRIGHT JD,PANDEY RK,et al.Pan-genotypic anti-HCV activity of SB 9200 assessed in the'capture-fusion'replication assay[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.
|
|
[34] SPELLMAN M,MARTIN JT.Treament of chronic hepatitis B infection with DV-601,a therapeutic vaccine[C]//46th annual meeting of the European Association for the Study of the Liver(EASL).Berlin,2011.
|
|
[35]FELD JJ,COLLEDGE D,SOZZI V,et al.The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging[J].Antiviral Res,2007,76(2):168-177.
|
|
[36]BENGSCH B,MARTIN B,THIMME R.Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].J Hepatol,2014,61(6):1212-1219.
|
|
[37]SHERMAN AC,TREHANPATI N,DAUCHER M,et al.Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir[J].AIDS Res Hum Retroviruses,2013,29(4):665-672.
|
DownLoad: